Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 3Turcot syndrome 2Medulloblastoma 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rhabdoid Tumor 1Recurrence 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Pinealoma 1Peutz-Jeghers Syndrome 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Mouth Neoplasms 1Locally Advanced Rectal Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Ependymoma 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Adenomatous Polyposis Coli 1

Interventions

lutetium Lu 177 dotatate 2Temozolomide 2ONC206 2Etoposide 2Cyclophosphamide 2Bevacizumab 2olaparib 1neratinib 1ibrutinib 1fenofibric acid 1etoposide phosphate 1brigatinib 1Watchful Waiting 1Thalidomide 1Restraint, Physical 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Linear Energy Transfer 1Irinotecan 1Elasticity Imaging Techniques 1Cytarabine 1Celecoxib 1Automobiles 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ependymoma × Celecoxib × Clear all
NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting
232 enrolled
CNS

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡